Introduction. Recent advances in the diagnosis and treatment of influenza virus infections include: (1) rapid bedside diagnosis methods with simple commercially available tests; and (2) Food and Drug Administration approval of treatment for children 1 year of age and older with neuraminidase inhibitor drugs. For proven benefit antivirals should be used within 2 days of onset of symptoms.
INTRODUCTION
Although recent influenza seasons have been associated predominantly with influenza A virus (H3N2), in some communities about-one third of cases have been caused by influenza B.
1 Until 1999 two antiinfluenza drugs (amantadine and rimantadine) were Food and Drug Administration-approved for treatment and/or prophylaxis of influenza A. Neither drug was effective for the treatment or prophylaxis of influenza B. 1 In 1999 the Food and Drug Administration approved two new antiinfluenza drugs, zanamivir and oseltamivir. Both are inhibitors of neuraminidase, and both are effective against influenza A and B.
2 Based on studies in the United States and elsewhere, these neuraminidase inhibitors appear to have fewer adverse effects than amantadine. Zanamivir in healthy hosts appears to have the lower reactogenicity. Zanamivir (Relenza), manufactured by Glaxo-Wellcome, is administered by inhalation by means of a rotodisk inhaler. 3, 4 Oseltamivir (Tamiflu) is manufactured by Roche Holdings and administered orally once or twice a day. 5 By early November, 1999, sporadic cases of influenza A had been reported in Alaska, Oregon and Maryland, and on November 18 our office laboratory reported the first positive test for the 1999 to 2000 influenza season.
To achieve maximum efficacy all antiinfluenza drugs must be started within 48 h of the development of influenza symptoms. The rapid antigen tests were developed for early detection of influenza viruses. There have been major advances in the past several years in the approval of rapid, simple, in-office kits for the detection of influenza viruses, including both A and B. However, there had been no head-to-head comparison studies of the four approved rapid detection tests. Thus in a performance (quality assurance) exercise, we processed all samples from patients with suspected influenza using the four approved diagnostic methods: (1) Z Stat Flu (ZymeTx, Inc., Oklahoma City, OK); (2) Directigen Flu (Becton Dickinson, Cockeysville, MD); (3) Quickvue Influenza Test (Quidel, San Diego, CA); and (4) Biostar OIA test for influenza (Biostar, Inc., Boulder, CO).
PATIENTS AND METHODS
During the 1999 to 2000 epidemic symptomatic patients seen at the private practice of one of the authors provided specimens as described below which were collected according to manufacturer's directions. Throat swabs only were used to collect the specimens for the Z Stat Flu Kit. Tests were conducted according to manufacturer's recommendations. With the exception of the test using Directigen, which was run immediately, specimens were tested within 12 to 24 h (tests were run in parallel). Specimens were frozen first at Ϫ20°C for up to 3 days and shipped in transport medium to the Virology Research Laboratory of the Virginia State Health Department for culture where they were stored at Ϫ60°C until cultured. After we were notified by the Virginia State Health Department of their inability to process additional specimens, a commercial laboratory cultured a fraction of the samples. Only those samples from which a culture result was available were used in the analysis. The results of the various tests were compared with results of the viral cultures including the direct immunofluorescence test (DFA) (Chemicon International, Temecula, CA) results. Fisher's exact test and the chi square tests were used for statistical comparison.
Because the patients were managed according to the results, each specimen was run as quickly as possible to detect influenza, for influenza A using the Directigen and the Quickvue alongside to help in the diagnostic process if influenza B was present. If time permitted (we had only one laboratory technologist on duty at any time), the Flu OIA was often run at the same time as the Directigen and the Quickvue. If the workload did not permit running the Flu OIA in conjunction with the Directigen and Quickvue, then it was batched along with the Z Stat Flu and run as soon as possible (within 24 h).
Twenty-five of the specimens were collected as nasal washings along with a throat culture for the Z Stat Flu. Previously (in an unpublished experience) one of us (RS) had noticed that specimens collected by nasal swabs performed comparably with those in which nasal washes were used as sources for testing for influenza viruses. The remaining specimens were collected as two nasal swabs and a throat swab. One nasal swab was used undiluted to run the Flu OIA, whereas the other nasal swab was mixed in 2 to 3 ml of saline to make an emulsate; 125 l were used to run the Directigen Flu A, and 250 l were used to run the Quickvue test. The remainder of the emulsate was transferred to transport medium to be cultured by either the State of Virginia Epidemiology Laboratory or the American Medical Laboratory Virology Laboratory. Thc throat swab was used to run the Z Stat Flu test. The tests were performed according to manufacturer's directions. Table 1 shows previously published information about the four tests compared side by side in terms of technology and cost, as well as reported sensitivity and specificity 6 of each test.
RESULTS

Epidemiology.
Our study began on December 13, 1999, and ran until January 13, 2000. A total of 152 patients were tested: 64 were 3 years of age or less; 42 were between 3 and 10 years of age; 21 were between 10 and 15 years of age; 14 were between 15 and 20 years of age; and 11 were older than 21 years. Laboratory results. Specimens from 116 of 152 (76%) patients and some of their parents (see above) were available for influenza culture; for 88 of these culture was performed at the State Health Department laboratory, and for 28 culture was performed at a local commercial medical laboratory. Influenza virus A was detected in 58 of 118 (49%) specimens, in 10 (17%) of these only by DFA (Chemicon) of the samples. Other viruses were recovered from 10 of the 116 patients (8.6%). Nine had adenoviruses (one of them also had influenza A) and the other one had respiratory syncytial virus.
With viral culture-DFA results as the standard, the results of the comparison are shown in Table 2 . The sensitivities of the four tests ranged from 72% in the case of Z Stat Flu to 95% for Directigen Flu A and Quickvue. Specificity ranged between 76 and 84%. Positive tests had positive predictive values of 80 to 86%. Although the negative predictive values ranged from 75% in the case of Z Stat Flu to 94% for Directigen Flu A, Z Stat Flu differed significantly in negative predictive values from the other three tests.
DISCUSSION
In this study, conducted in a pediatric outpatient population where rapid tests were compared with DFA-tissue culture, Directigen Flu A, Quickvue and Biostar appeared equivalent in sensitivity, specificity and positive and negative predictive values, but Z Stat Flu was not as sensitive as the others and its negative predictive value and efficacy were lower than the other three tests. The high sensitivity of Directigen Flu A reflects the fact that our isolates were predominantly influenza A. The high sensitivity reported in our experience, when compared with those reported in the literature, could reflect the possibility of a higher antigenic load present in the source, i.e. a population made of primarily pediatric patients as compared with an adult population. 7 We conducted the tests on relatively noninvasive samples collected from nasal washing and/or swab of nares or throat. They are touted as the best clinical samples. 8 Covalciuc et al. 9 found sputum and nasal aspirates to be superior to throat swabs in detecting the influenza virus. Because the comparison applied to only those samples where influenza presence was tested by culture and/or immunofluorescence, there could have been instances in which the rapid test was truly more sensitive than the culture and was thus penalized in the analysis. Thus it seems likely that the high sensitivity for these tests that we noted and specificities that are good but less than desirable could be explained by a reduced sensitivity of the culture. We also recognize that storing samples for 3 days at Ϫ20°C and delaying the testing by culture was less than optimal. Such concern may be reinforced by detecting the virus in some samples through DFA only with an accompanying negative culture. In our hands all methods were relatively easy to perform. Directigen proved relatively simple and expeditious, its shortcoming being its detection of Flu A only; Flu OIA was similarly easy to perform in 15 min but required more counter space. Quickvue was simple to perform with results available within 15 min. Z Stat Flu was the most cumbersome to handle, difficult to evaluate in weakly positive situations and took ϳ30 min for an answer. Although this test appeared less sensitive than the other three tests, there is the possibility that specimen storage at 4°C until tested could have led to loss of enzyme activity for those specimens tested ϳ24 h from collection. We do not have sample material left with which to confirm or deny this possibility.
Because of the lower sensitivity noted in the adult population (ϳ80%), the tests may have usefulness in a limited number of settings. 10 Awareness of those populations which could benefit from rapid diagnosis is important. Within the recognized limitations rapid diagnostic tests offer us the possibility of early diagnosis as well as the opportunity to institute effective antiviral therapy early in the illness. Background. Outbreaks of nosocomial influenza virus infections have been described rarely during childhood and even less so in the neonatal period.
Methods. We report 30 neonates admitted to 2 neonatal intensive care units with nosocomial influenza A virus infection, which occurred in 2 outbreaks during 1999. Risk factors for infection were evaluated, and control measures were adopted. Virus was detected by indirect immunofluorescence antibody screen. Any infant with nasopharyngeal aspirate positive for influenza A virus was considered infected.
Results. Of 95 infants screened 30 were positive for influenza A virus (31.5%). Mean birth weight was 1622 g, and mean gestational age was 31 weeks in the infected group. In the noninfected group mean birth weight was 2594 g and mean gestational age was 36.4 weeks. Low birth weight, short gestational age, twin pregnancy and mechanical ventilation were identified as risk factors for infection. Clinical symptoms were seen in 22, and 8 were asymptomatic. Clinical features were predominantly respiratory and digestive. The outcome was favorable in all cases.
Conclusions. Infection by influenza virus has to be considered as a possible cause of nosocomial infection in the neonatal period. Control measures and prevention are important.
INTRODUCTION
Influenza virus is a cause of annual outbreaks of acute respiratory disease and is responsible for considerable mortality and morbidity in all age groups. 1 Improvements in rapid diagnosis techniques for viruses have revealed that the influenza virus is a cause of acute respiratory infections in children and could be responsible for nosocomial infections.
2, 3 Outbreaks of influenza virus infections have been described infrequently in children and even less so in the neonatal period. In a review from 1959 to 1994, Evans et al. 4 described 17 reports of outbreaks of influenza virus infections in hospitals, 5 in children and 2 in neonates. 5, 6 Munoz et al. 7 and Cunney et al. 8 reported 2 further outbreaks in neonatal intensive care units (NICUs).
We report 30 cases of influenza A virus infection occurring in 2 neonatal intensive care units (NICUs) in Barcelona (Catalonia, Spain).
MATERIALS AND METHODS
Population. We report 30 cases of neonates with a diagnosis of nosocomial infection with influenza A virus. They were admitted to the neonatal intensive care units of 2 Barcelona hospitals that share the same virology laboratory. The cases occurred in 2 outbreaks, in February to May, 1999, in one hospital (10 cases) and in October, 1999, in both (8 and 12 cases, respectively).
In February, 1999, two premature infants (twins) developed respiratory symptoms. The virologic study was positive for influenza A virus. Two months later we detected another infant also symptomatic (April). In this period no study was conducted, nor were control measures adopted. In the next month (May), on detecting three new cases with symptomatic influenza A virus infection, a systematic study was undertaken and control measures were adopted. A virologic study was performed among all admitted neonates and personnel with access to the neonatal unit (including the parents of the infants admitted), and four new cases were identified in the next 2 days. The infants who were negative were screened every 3 days or if they developed clinical symptoms.
In October a systematic study was conducted among all infants and personnel in the two hospitals after detecting the first case.
Any infant with a nasopharyngeal aspirate positive for influenza A was considered infected. The symptomatic cases were those who presented any type of symptomatology not explained by other causes within the 48 h before or after obtaining the sample.
Birth weight, gestational age, twin pregnancy and mechanical ventilation at times of the outbreak were evaluated as possible risk factors for infection. Data were analyzed using Epi-Info (Release 6.04; Centers for Disease Control and Prevention, Atlanta, GA).
Laboratory methods. The virus was detected by indirect immunofluorescence antibody screen (IFA) or viral cultures in nasopharyngeal secretions following standard procedures.
9, 10 IFA (Respiratory Panel 1: Viral screening and identification IFA kit; Light Diagnostics, Temecula, CA) was used to detect influenza A and B viruses, respiratory syncytial virus, parainfluenza viruses and adenoviruses (ADV).
Furthermore NPS were inoculated onto monolayers of four types of tissue cultures, MRC5, A549, Hep-2 and Madin-Darby canine kidney cells, known to be sensitive for detection of the most common respiratory viruses (influenza A and B viruses, respiratory syncytial virus, parainfluenza viruses, ADV, enteroviruses and rhinoviruses). After incubation at 37°C the inoculated tubes were observed every other day for 14 days or until a cytopathic effect was apparent. Viral isolates were identified by immunofluorescence techniques with the use of monoclonal antibodies (Respiratory Panel 1: Viral screening and identification IFA kit; Light Diagnostics).
The subtyping of the influenza A viruses isolated from these newborns was not available, but as judged by the virus laboratory records different strains of the H3N2 and H1N1 subtypes were circulating in our community at the times of the outbreak.
Control measures. The infants infected with influenza A virus were cohorted in a separate room and were cared for in isolettes. Control measures for crossinfection were initiated and consisted of respiratory isolation and use of masks, gown and gloves by all personnel in contact with the babies. Hand washing was emphasized. Staff were restricted to working in separate areas. No changes in airflow in rooms that housed known cases and contacts were carried out. We performed amantadine prophylaxis (100 mg twice daily for 7 days) and vaccination of all personnel (except two pregnant workers) including parents of infants in the NICUs. Respiratory isolation was maintained until 15 days after vaccination.
No one with respiratory symptomatology and/or virologic positive result was allowed access to the NICUs.
RESULTS
During the periods mentioned 95 newborns were screened for the influenza A virus in the 2 centers, and 30 were positive (31.5%). The population infected was composed of 30 neonates with a mean birth weight of 1622 g (range, 700 to 3140) and mean gestational age of 31 weeks (range, 26 to 37). Twenty-eight were premature, and in 14 the gestational age was Ͻ32 weeks. Thirteen weighed Ͻ1500 g. The mean birth weight and mean gestational age in the 65 neonates not infected were 2594.4 g (range, 1295 to 4484) and 36.4 weeks (range, 28 to 42). The infected group showed significantly lower birth weight and shorter gestational age than the noninfected group (P Ͻ 0.01). In addition twin pregnancy and mechanical ventilation were identified as risk factors for infection with odds ratios of 8.48 and 6.54, respectively (Table 1) . Two parents and one nurse were positive in the first outbreak. No definite source was identified in the second outbreak.
In May no new cases were detected after 48 h of initiation of control measures. On the other hand, in October the outbreaks lasted for 16 days in the first hospital and 21 days in the second hospital. After this period none of the infants presented symptoms, and viral screening was negative during 7 days after the last positive case. All noninfected infants remained negative. Cultures were performed only in six patients, three were positive and three negative; no additional cases were identified.
The clinical symptoms were basically respiratory and digestive. Nineteen neonates developed respiratory symptomatology, 11 in the form of mild respiratory distress with or without apnea, and required supplementary O2 (24% and 30%); 2 newborns who underwent mechanical ventilation required increased fractions of inspired oxygen. The mean duration of the symptoms was 8 days (range, 3 to 10 days). The remaining 8 patients developed upper airway infection symptoms with rhinorrhea, cough and sneezing that remitted in 2 to 3 days. Four infants developed digestive symptomatology involving poor feeding, vomiting and abdominal distension lasting for 5 to 7 days. One newborn developed respiratory and digestive symptoms simultaneously. In no infant was necrotizing enterocolitis suspected. The remaining 8 patients did not develop symptoms and were detected in the course of screening during the outbreak. Only one neonate with symptoms of upper respiratory airways infection (URI) had fever.
Peripheral blood leukocyte count and C-reactive protein were always within the normal range. Chest radiography was normal or revealed a diffuse and mild infiltrative pattern, except in one case where bilateral alveolar infiltrates developed.
The outcome was favorable without specific treatment except in four cases: two neonates on mechanical ventilation; one newborn with moderate respiratory distress and abnormal chest radiography; and another with digestive symptomatology, severe abdominal distension and septic appearance, where amantadine therapy was given orally as 5 mg/kg/day for 5 days.
DISCUSSION
The influenza virus is a cause of nosocomial infections with attack rates between 4 and 71%. 2, 11, 12 In NICUs, however, nosocomial infection outbreaks caused by influenza virus have been infrequently reported. To the year 2000 only 4 reports had been published, [5] [6] [7] [8] and in 3 of them the number of cases was small. The largest series published by Cunney et al. 8 includes 19 patients.
Our series includes 30 infants with influenza A virus infection diagnosed by immunofluorescence, a technique that has shown a sensitivity and a specificity of 75 to 88% and 96 to 100%, respectively, in different studies. 13, 14 The symptomatology was mainly respiratory and digestive and was similar as regards clinical manifestations, duration and outcome to those published in series described. [5] [6] [7] [8] The digestive symptoms were mild, nonspecific and self-limiting but had not been described in previous reports. The duration of the symptoms is clearly shorter when the clinical picture is that of URI. Fever is not a constant manifestation and in fact was seen in only one newborn. As in the series described complementary explorations were not useful for diagnosis of infection. In all symptomatic neonates a chest radiograph was performed and only one patient showed infiltrates.
Despite the clinical characteristics of the infants affected (low birth weight, short gestational age, neonatal problems, etc.), the clinical picture of influenza A infection was mild to moderate and no case was fatal. We did not detect long term sequelae related to influenza A virus infection. This is in agreement with previous reports that generally assumed that influenza is a mild infection in the neonatal period caused by acquisition of maternal antibodies. 15 The four cases in our series treated with amantadine were severely ill previously, and the role of influenza A infection on clinical course is difficult to evaluate.
On the whole the outcome is favorable. Only 2 deaths were reported in the series described and in the one by Munoz et al., 7 it clearly cannot be attributed to the influenza virus infection, given the severity of the cardiopathy and the time of death, which occurred after remission of the initial symptomatology. However, epidemiologic data showed that mortality can reach 2 to 4.6% in patients with underlying severe illness, especially under the age of 6 months. 16 In our series twins showed a major risk of infection. According to the report of Cunney et al. 8 it seems more likely that transmission of influenza A between siblings occurs through parental contact, because parents handle both siblings during a single visit to the NICU. We also found low birth weight and short gestational age as well as mechanical ventilation as risk factors for infection.
It is likely that the source of our outbreaks is a community strain introduced in our units by either the staff members or infants' parents. The fact that one outbreak began during times of low viral activity in our community is very surprising. Knowledge of peaks of viral activity in the community should alert the neonatologist to consider influenza A infection in the diagnosis of respiratory distress, digestive symptoms or sepsis-like appearance in premature or term newborns, especially when twins are affected simultaneously. The symptoms can begin early (age 3 days) or late (age 2 months or more). The available space in our units is smaller than the design standards recommended for Level III NICUs. It is likely that overcrowding facilitates the spread of the outbreaks. Overcrowding and understaffing are recognized factors for spread of bacterial and viral pathogens, but this has not been demonstrated for influenza infections. 17, 18 In view of the great potential of the influenza virus to spread because of its short incubation period (1 to 3 days) and airborne transmission, it is fundamental to set up control measures as soon as possible. Clinical suspicion and rapid diagnostic techniques allow confirmation within hours. It is necessary to tighten control measures for cross-infection by using gloves and masks, hand washing and, if possible, isolation of infected infants. In May the control measures were highly effective in aborting the outbreak because no new cases were detected 2 days after implementation; on the other hand the October outbreaks lasted for 16 and 21 days in the two hospitals after initiation of the same control strategy. It is possible that this fact can be explained by differences in the viral activity in our country in these two periods, because it is unusual to have influenza infection in the spring-summer period.
The fundamental strategy of prevention is vaccination of all personnel in contact with newborns, including parents, and preventing nonvaccinated personnel or those with compatible symptomatology from access to the unit. Regrettably the vaccination rate of health workers is extremely low in our setting (vaccination rate of 2% in our unit before the outbreaks) in accordance with rates reported of 4 an 17%. 8, 19, 20 In addition the first outbreak began 6 months after the period recommended for vaccination and the second at the beginning of it, when in theory the immunity of care workers was lower.
Adverse drug effects had been reported with amantadine administration in the newborn, but we did not detect adverse reactions in our four treated patients. Resistance to amantadine can develop rapidly, 7 rendering treatment useless. This could account for the poor outcome of the neonate that died in Cunney's series 8 with persistently positive nasopharyngeal aspirates despite therapy.
Chemoprophylaxis with amantadine among health workers is not free from side effects; hence the use of new neuraminidase inhibitors such as zanamivir and oseltamivir could play a role in the control of future epidemics. They appear to have fewer adverse reactions 21, 22 and have proved effective in the prevention of infection by influenza virus. 23, 24 In conclusion infection by influenza virus should be considered as a possible cause of nosocomial infection in neonatal units. Morbidity is far from negligible, although the outcome is generally favorable without specific treatment. Control measures and especially prevention by vaccination of all personnel in direct contact with neonates are fundamental. 
Interpretation of the tuberculin skin test reaction by pediatric providers EDWARD R. CARTER, MD AND CHARLOTTE M. LEE, MD
Background. The tuberculin (TB) skin test is widely used, but it is not easy to read. There are few data on how well pediatric care providers interpret the TB skin test or on the success of various methods used to read the skin test reaction.
Objective. To determine the ability of pediatric care providers to correctly read a positive TB skin test reaction and to identify the most successful method of measuring a TB skin test reaction.
Methods. Twenty nurses, 16 staff pediatricians, 13 residents and 8 medical students who were working in a large pediatrics clinic were asked to read a 15-mm TB skin test reaction of a known converter. The study participants read the skin test using any technique they wished. The primary outcome measure was the percentage of providers who read the TB skin test as >10 mm (considered a correct reading).
Results. Seventy-seven percent (44 of 57) of the participants interpreted the TB skin test as >10 mm, but 18% (10 of 57) of them read the skin test as negative (<5 mm). The participants used a variety of interpretation techniques with 18 using the ballpoint pen technique. Participants who used the pen technique were significantly more likely to read the skin test as >10 mm compared with those who used other methods (94% vs. 69%; P ‫؍‬ 0.04). Pen technique users were also significantly less likely to measure the reaction as <5 mm (0% vs. 26%; P ‫؍‬ 0.02).
Conclusions. Many providers, regardless of professional training and experience, read a 15-mm TB skin test reaction as >10 mm, but a significant minority interpreted it as negative. Use of the pen technique may decrease the number of false negative readings. Specific instruction on use of the pen technique to read TB skin tests should be incorporated into medical training curriculums. INTRODUCTION The tuberculin (TB) skin test with purified protein derivative is the recognized method of choice for diagnosing infection with Mycobacterium tuberculosis 1 , but TB skin tests are not easy to interpret. In areas with a low prevalence of tuberculosis infection, providers may not have the opportunity to read many positive TB skin tests, and this can result in inaccurate interpretations. Both false positive and false negative TB skin test readings can lead to inappropriate treatment decisions. Therefore it is important to determine how well health care providers interpret TB skin tests and also to identify any measurement techniques that can increase the frequency of correct readings.
There are several methods of interpreting TB skin tests, with the most widely accepted ones being the palpation method and the ballpoint pen technique. The American Thoracic Society recommends using palpation to assess induration but also states that the ballpoint pen technique might decrease interobserver variability. 1 The 2000 Red Book suggests using the ballpoint pen technique and does not mention the palpation technique. 2 Kendig et al. 3 reported that 30% of pediatricians, nurses and residents attending a pediatric conference read a 15-mm TB skin test reaction as Ͻ10 mm, but only 2 of the 107 participants used the pen technique. Several investigators have reported that use of the pen technique results in less inter-and intraobserver variability compared with using palpation alone. 4, 5 Others who compared the pen technique directly to the palpation method found them comparable. 6 -8 In these studies a small number of providers read the TB skin tests, and the majority of the skin test reactions were Ͻ10 mm. The pen technique has not been evaluated in a setting of a large number of providers inexperienced in reading TB skin tests. We wished to determine how well a group of pediatric care providers with a wide spectrum of training and experience interpreted a positive TB skin test. In addition we wanted to identify any particular method that could decrease misreadings.
SUBJECTS AND METHODS
Participants and procedures. We asked health care providers, nurses, staff pediatricians, residents and medical students who were working in the pediatrics clinic to participate in the study. We obtained verbal but not written informed consent, and the investigators made it clear that participation in the study was purely voluntary. Fifty-seven care workers agreed to participate, and none refused. The participants were divided into 4 groups: 16 staff pediatricians; 13 pediatric and family practice residents; 20 nurses [5 RNs and 15 licensed practical nurses (LPNs)]; and 8 medical students (4 third year and 4 fourth year). We included LPNs because at our institution LPNs interpret TB skin test reactions. One of the investigators, a white man and a known purified protein derivative converter, had a standard 5-unit tuberculin dose placed subcutaneously on the volar aspect of his left arm. Approximately 48 h later, both the Chief of Pediatric Infectious Diseases and the Chief of Allergy and Immunology independently measured the reaction. They used the ballpoint pen technique (their choice); this consisted of running the tip of the ballpoint pen to the edge of induration to demarcate the site of induration. The widest diameter of induration provided the value for the skin test reaction. One of the "official readers" measured the reaction to be 15 mm and the other 14 -16 mm, so we chose 15 mm as the valid measurement. On that same day, during a 6-h period, we asked the study participants to interpret the skin test reaction. We told each provider to use any method they desired, and we provided a ruler, tape measure and pen, but only on request. After each measurement we carefully cleansed the skin test site with alcohol before moving on to the next interpreter. At the end of the study, the skin test site was remeasured to determine whether the size of the induration had changed from the beginning to the end of the study, and it was still 15 mm.
Outcome measures and statistical analysis. The primary outcome measure was the percentage of providers who read the TB skin test reaction as Ն10 mm. We considered this a correct interpretation and any value Ͻ10 mm as a misreading. We chose this cutoff because we felt that anyone who read a 15-mm skin test as Ͻ10 mm had definitely misread it. Secondary measures included the number of providers who interpreted the reaction as negative (defined as Յ5 mm) and the number of providers who used the ballpoint pen technique. Only providers who used the ballpoint pen to appropriately mark and then measure the diameter of the induration were included in the ballpoint pen technique group. We also analyzed differences in these outcome measures between those participants who used the pen technique and those who did not. We used the Fisher's exact and chi square tests to assess intergroup differences among the four groups (nurses, medical students, residents and staff physicians).
RESULTS
Fifty-seven care workers participated in the study, and all but two of them knew to measure the size of the induration rather than the erythema. Measurement techniques ranged from palpation to simple visual inspection, and 32% of the participants used the pen technique. All but one participant used a ruler or tape measure to determine the actual size of the reaction. Less than one-half of the participants remembered receiving formal training on how to read a TB skin test or having actually seen a positive TB skin test reaction.
There were no significant differences between the 4 groups of providers with respect to how well they interpreted the skin test reaction (Table 1) . Seventyseven percent (44 of 57) of the participants interpreted the reaction as Ն10 mm, but this meant that 23% failed to correctly interpret the skin test reaction. In addition 10 participants (18%) read the reaction as Յ5 mm (Table 1) . Ninety-four percent of the participants who used the pen technique measured the skin test reaction as Ն10 mm compared with 69% of those who used other methods (P ϭ 0.04; Table 2 ). In addition no one who used the pen technique read the skin test reaction as Յ5 mm compared with 26% of those who used other methods (P ϭ 0.02; Table 2 ).
DISCUSSION
In this study we identified several problems with the interpretation of a positive TB skin test reaction. First
we found that many providers, whether nurses, residents, medical students or staff physicians, could not remember having received formal training in skin test interpretation. Many of them had not even seen a positive TB skin test. Second we found that approximately one-fifth of the providers interpreted a 15-mm TB skin test reaction as Ͻ10 mm whereas one in six actually read it as negative (Յ5 mm). Finally use of the pen technique was associated with a decrease in the number of incorrect readings.
Interpretation of a TB skin test is not easy, and errors in reading it can result in patients receiving inappropriate treatment. False positive readings, which are more likely when the prevalence of TB infection is low, can lead to overprescribing antituberculous medications, whereas false negative readings may delay appropriate treatment. In our study 23% of providers would have inappropriately withheld treatment based on their misreading of a positive TB skin test as Ͻ10 mm. This is an unacceptable error rate and underscores the necessity of finding ways to improve the accuracy of skin test interpretation.
Other groups of providers might perform better with respect to reading TB skin tests than the participants in our study, but we believe that our study participants were fairly representative of the medical population at large. The 4 groups in our study differed widely in their training and experience, yet they all performed comparably. Furthermore in a similarly designed study by Kendig et al., 3 33% of 107 pediatric health care providers misread a 15-mm TB skin test reaction as Ͻ10 mm. Only 2 providers in that study opted to use the pen technique, so that method could not be evaluated.
We found that the participants in our study who used the pen technique had fewer false negative skin test readings. This suggests that the pen technique can help providers interpret a positive TB skin test more accurately. In studies that have compared the pen technique to palpation for both intraobserver and interobserver variability, the pen technique fared either better than or the same as palpation. 5, 6 In these studies the persons reading the skin tests were quite experienced in skin test interpretation. Bouros et al. 8 found that a single inexperienced reader interpreted 539 skin tests accurately with both the palpation method and the pen technique. However, in this study the "inexperienced" provider rapidly gained experience with both methods of interpretation as hundreds of skin test reactions were read. In our study multiple providers interpreted a single test, so there was no chance for our participants to gain experience during the study. We found that the pen technique definitely improved the accuracy of TB skin test interpretation in a group of providers who were not experienced in reading positive skin tests. Thus the pen technique may not be necessary for persons experienced in interpreting skin tests but can be helpful in enabling those who are inexperienced to measure skin test reactions correctly. (5) 10 (18) * There were no significant differences between the four groups; P ϭ 0.08, chi square test. † There were no significant differences between the four groups; P ϭ 0.26, chi square test. ‡ Numbers in parentheses, percent. Our study had several limitations. We had only one skin test reaction for participants to read, and this was positive at 15 mm. Thus we were not able to evaluate false positive rates. It would have been useful to have had a truly negative skin test reaction with some erythema and no induration to be able to assess for the accuracy of negative readings. In addition we had only 10 to 15 participants in each of our subgroups. With more participants we might have been able to more clearly identify intergroup differences as well as to more precisely determine the benefit of using the pen technique. Also we did not prospectively assess the utility of the pen technique or compare it directly with the palpation method. We were only able to evaluate the pen technique because enough of the participants opted to use it.
In conclusion we found that ϳ20% of medical health care providers in a pediatric clinic misread a 15-mm TB skin test reaction as Ͻ10 mm, a false negative rate similar to that reported by other investigators. Providers who used the pen technique had fewer incorrect readings. Thus the ballpoint pen technique may help reduce incorrect readings. We suggest that medical and nursing schools as well as residency programs institute formal training in TB skin test interpretation and consider teaching the ballpoint pen technique.
fied as microbiologically documented infection, clinically documented infection or unexplained fever. Clinical response to therapy was classified as success and failure.
Results. Ninety-five pediatric cancer patients with 120 febrile neutropenic episodes were randomized to receive empiric treatment with cefepime or ceftazidime. After 72 h of treatment, 82.8% (48 of 58) of the eligible patients in the cefepime group continued with unmodified therapy, compared with 87.9% (51 of 58) in the ceftazidime group. The neutrophil count was <100/ mm 3 at randomization for 76% of the patients in the cefepime group and 83% of those in the ceftazidime group; the median durations of neutropenia (<500/mm 3 ) were 8.5 and 6.5 days, respectively. Of the 96 evaluable episodes the overall success rate with unmodified empiric therapy until the end of the treatment course in the cefepime group was comparable with that in the ceftazidime group (69% vs. 71%, P ‫؍‬ 0.95). The response rate after glycopeptides were added to the regimens was 79.2% for the cefepime group and 77.1% for the ceftazidime group. The bacterial eradication rate was 33% for the cefepime group and 20% for the ceftazidime group (P ‫؍‬ 0.85), and the rates of new infections were 10.4% vs. 4.2% (P ‫؍‬ 0.67), respectively. Both study drugs were well-tolerated. Three (6.4%) patients in the cefepime group and 2 (4.3%) patients in the ceftazidime group died.
Conclusion. Cefepime appeared to be as effective and safe as ceftazidime for empiric treatment of febrile episodes in neutropenic pediatric cancer patients.
INTRODUCTION
Combination therapy with a beta-lactam and an aminoglycoside has been traditionally recommended for febrile episodes in neutropenic patients, but there is now evidence that monotherapy with a broad spectrum cephalosporin such as ceftazidime, cefepime or a carbapenem is as effective as combination therapy. [1] [2] [3] [4] Cefepime is an extended spectrum fourth generation cephalosporin with good activity against Gram-positive organisms, including methicillin-susceptible Staphylococcus aureus, alpha-hemolytic streptococci and some Staphylococcus epidermidis. It also has good activity against Gram-negative organisms, including Pseudomonas aeruginosa, and it resists degradation by Bush Group 1 beta-lactamases produced by Enterobacter spp. 5, 6 and Klebsiella spp. 7 The effectiveness and safety of cefepime for treatment of febrile episode in adult neutropenic cancer patients have been confirmed in several studies. 8 -14 Recent reports showed that cefepime is as effective and safe as ceftazidime for empiric treatment of febrile episodes in neutropenic pediatric patients with cancer. 15, 16 We have extended these studies with an open, randomized study comparing the efficacy and safety of cefepime and ceftazidime as empiric monotherapy of febrile neutropenia in children with cancer.
MATERIALS AND METHODS
Study design and patients.
A prospective, open label, randomized, comparative study in pediatric cancer patients was conducted at Chang Gung Children's Hospital from January 1, 2000, to April 15, 2001 . Hospitalized cancer patients age 2 months to 15 years were eligible for study if they became febrile during a period of neutropenia. Neutropenia was defined as an absolute neutrophil count Ϲ500/mm 3 . Fever was defined as a temperature of м38°C occurring at least twice in a 24-h period or as a single oral temperature of м38.5°C that was not related to administration of blood products. 17, 18 Patients were excluded if they had a history of allergy to penicillins or cephalosporins, had received any intravenous antibiotic during the preceding 96 h or treatment with any study drug within 30 days preceding randomization or had hepatic or renal diseases. Patients could enter more than once if they had new distinct episodes of febrile neutropenia separated by at least 30 days or recovery of neutropenia from prior episode by at least 2 weeks.
Antibiotic regimens. Patients were randomized in a 1:1 ratio and stratified by type of underlying malignancy (hematologic or solid tumor). Cefepime or ceftazidime was administered intravenously at a dose of 50 mg/kg/dose as two or three doses daily, at a maximum daily dose of 6 g. Modification of the initial treatment was permitted and included persistence or progressive worsening of clinical symptoms and signs of infection, resistant pathogen from culture results, emergence of new infections or at the discretion of the attending physician. Treatment was continued until the completion of an appropriate course of therapy for a defined clinical or microbiologic infection, or until resolution of fever and clinical signs and symptoms or at least 3 days, regardless of whether the neutrophil count had returned to normal or not.
Clinical and laboratory assessment. A complete medical history and physical examination were conducted for all patients on entry to the study. Laboratory examinations included a hematologic profile, liver function tests, renal function tests and chest radiograph when clinically indicated. Microbiologic evaluation included at least two sets of blood cultures (one peripheral and one from a central venous catheter if present), a urine culture when clinically indicated and cultures of any potential sites of infection.
All the patients were examined daily during therapy.
Additional evaluations and laboratory tests when appropriate were repeated during and at the end of the therapy. Side effects, adverse events or abnormal laboratory values that occurred during the study related to antibiotics were recorded and classified as not related, possibly related or definitely related to the study drug. Classification and evaluation of response. Febrile episodes were classified as microbiologically documented infection (both the site of infection and the organism were identified), clinically documented infection (the site of infection was identified, but no organism was isolated) or unexplained fever (infection was most likely in a febrile patient, but no site or organism was identified).
The clinical efficacy was evaluated at 72 h, at the completion of antibiotic therapy, and an overall response 7 and 30 days after treatment ended. Response to therapy was classified as success and failure. Success was defined as disappearance of fever, overall clinical improvement and eradication of any infecting organism without modification of antibiotic therapy and maintenance of response for at least 7 days after discontinuation of therapy. Failure was defined as persistence of fever or of the infecting organisms, any modification of antibiotic therapy, new infections or any death during treatment with the study drug.
New infection was defined as a new clinically or microbiologically documented infection that occurred either during therapy or after the discontinuation of antibiotic therapy.
An episode was classified as unevaluable for response to the study drug when there was a major protocol violation, nonbacterial infections, or early discontinuation or modification of the study drug before 72 h without adequate reason.
Analysis. An intent-to-treat analysis was performed for all eligible and evaluable patients. A second analysis for clinical response was done after excluding those unevaluable patients (failure in the intent-to-treat analysis).
Continuous variables in each study regimen were analyzed by Student's t test. Categoric variables in each group were compared by means of chi square or Fisher exact tests. Statistical significance was determined at P Ͻ 0.05.
RESULTS
Ninety-five patients who had 120 episodes of febrile neutropenia were randomized for treatment as 60 febrile episodes with cefepime and 60 episodes with ceftazidime. One hundred sixteen episodes in 93 neutropenic patients were eligible for study: 58 episodes with cefepime and 58 episodes with ceftazidime. Eighteen patients were enrolled more than once with distinct febrile neutropenic episodes. In the cefepime group 7 patients had 2 episodes and 2 patients had 3 episodes. In the ceftazidime group 6 patients had 2 episodes and 3 patients had 3 episodes. Six patients were randomized to receive a different study drug during distinct episodes of febrile neutropenia. Four episodes were ineligible for the following reasons: no cancer (1 in cefepime); skin rash (1 in cefepime); no fever (1 in ceftazidime); and receiving parenteral antibiotics within 96 h preceding randomization (1 in ceftazidime).
Characteristics of the patients during febrile episodes. Demographic data and clinical characteris- tics by episodes are shown in Table 1 . There were no important differences between the treatment groups for the characteristics described. Causes of neutropenic fever are shown in Table 2 . Clinical response. After 72 h of treatment 48 of 58 (82.8%) of the patients continued with unmodified therapy in the cefepime group, compared with 51 of 58 (87.9%) in the ceftazidime group (P ϭ 0.94). The clinical responses of the evaluable episodes are shown in Table 3 .
Among the evaluable episodes with treatment modification, vancomycin was added to the regimen in 11 of the 15 episodes in the cefepime group and was the initial modification in 6 episodes. Nine episodes receiving cefepime were modified to ceftazidime (5 during the primary infection and 4 during a recurrent fever or a new infection). In the ceftazidime group vancomycin was added to the empiric regimen in only 5 of the 14 episodes. Amphotericin B was added in 3 episodes each with cefepime and ceftazidime. Although vancomycin was added most frequently in the cefepime group, the overall success rate after the addition of glycopeptides increased to 79.2% (38 of 48) with cefepime and 77.1% (37of 48) with ceftazidime.
Reasons for treatment failure are shown in Table 4 . Additional analyses stratifying the clinical response by cancer diagnosis, duration and severity of neutropenia are shown in Table 5 .
Bacteriologic efficacy. The six Gram-negative blood isolates from the cefepime group, Klebsiella oxytoca extended spectrum beta-lactamase (ESBL), Klebsiella pneumoniae, Salmonella choleraesuis, Salmonella enteritidis B, Moraxella catarrhalis and Escherichia coli, were susceptible to cefepime. Cefepime eradicated all of the isolated pathogens, but new infection occurred in one patient; there was persistent fever and recurrent fever in 2 and 1 episodes, respectively. Among the three blood isolates from the ceftazidime group, methicillin-resistant Staphylococcus aureus and Acinetobacter baumanii were resistant and E. coli was susceptible to ceftazidime in vitro. Campylobacter jejuni was isolated from the stool in one patient and E. coli, Enterococcus and methicillinresistant S. aureus were isolated from a wound in another patient in the ceftazidime group.
New infections. New infections occurred in five patients in the cefepime group and two patients in the ceftazidime group (P ϭ 0.67). The organisms causing new infections in the cefepime group were viridans Streptococcus, Neisseria sp., Stenotrophomonas maltophilia, A. baumanii, methicillin-susceptible S. aureus and K. pneumoniae ESBL. In the cefepime group one patient had recurrent fever and clinical sepsis but no evidence of bacteremia; two patients had a polymicrobial infection. The organisms causing new infections in the ceftazidime group were viridans Streptococcus and Enterobacter cloacae. Overall six of seven (85.6%) new infections were microbiologically documented.
Intent-to-treat analysis. The response rates were compared in an intent-to-treat analysis of 96 eligible episodes (Table 4) . A high success rate was obtained with both study drugs in patients with unexplained fever, 89% (25 of 28) and 82% (28 of 34) in the cefepime and ceftazidime groups, respectively. The success rates for microbiologically documented infections were 28.6% (2 of 7) and 14.3% (1 of 7) in the cefepime and ceftazidime groups, respectively. For the clinically documented infections, 26% (6 of 23) of the cefepime and 29% (5 of 17) of the ceftazidime group had a successful response.
Tolerability. There were no reports of nausea, vomiting, diarrhea related to either cefepime or ceftazidime. Cefepime was discontinued in one patient with a skin rash considered probably related to the drug.
Deaths. Three patients in the cefepime group died. One patient with leukemia died of causes directly related to a new infection with S. maltophilia and A. baumanii sepsis after eradication of K. oxytoca ESBL in the blood. Two patients, one with lymphoma and one with leukemia, died of progressive sepsis syndrome 
DISCUSSION
Several studies have demonstrated that monotherapy with new extended spectrum cephalosporins (ceftazidime or cefepime) or carbapenems is an effective alternative to traditional combination therapy in febrile neutropenic patients. 2, 4 The Food and Drug Administration of the United States has approved cefepime for the empiric monotherapy of febrile neutropenia in adults.
This study has included a large group of profoundly neutropenic patients (neutrophil counts of Ͻ100/mm 3 at entry). Most patients in the cefepime group had leukemia, whereas more patients in the ceftazidime group had solid tumors.
In an analysis comparing febrile episodes in children and adults, bacteremia occurred in 22%, clinically documented infection in 19% and fever of unknown origin in 49% in febrile neutropenic episodes in children. 20 The incidence of bacteremia (8.7%) in our study was low compared with that report. However, the incidence of documented infections and unexplained fever was comparable with that reported in a recent comparative trial of ceftazidime and cefepime in pediatric patients. 15 Studies comparing cefepime and ceftazidime monotherapy in children with febrile neutropenic episodes are summarized in Tables 6 and 7 . Our study achieved a success rate of 69% with cefepime compared with 71% with ceftazidime. However, the numbers of evaluable patients are too small to make any statistical conclusion. Data from previous studies in children 15, 16 and in this study showed overall success rates of 68.7% for cefepime and 67.9% for ceftazidime. These results indicate that cefepime appears to be as efficacious as ceftazidime in this setting.
Our study was conducted at a single institution. The number of patients with microbiologically documented infections was small, and the pathogens reflected the microbiology in the cancer patients of our institution. In contrast to the current trend in the western countries, 21, 22 we did not observed a complete shift toward Gram-positive organisms. This could be the result of the relatively low frequency of central venous catheter implantation in our patients. Thirty percent of the febrile episodes in both treatment groups required a modification. Modification of antimicrobial therapy is a reality in clinical practice in the treatment of febrile neutropenia. 1, 2 In our study antibiotics were added more often in patients treated with cefepime than with ceftazidime. In particular glycopeptides were added as modification in 23% (11 of 48) of the evaluable episodes treated with cefepime compared with 10.4% (5 of 48) of those in which ceftazidime was received empirically. This finding cannot be explained by the higher incidence of documented Gram-positive infections observed in the cefepime group; indeed most patients received glycopeptide addition without documentation of a resistant microorganism. Despite the increased activity of cefepime against Gram-positive organisms, 5 it did not lessen the need for glycopeptide addition in our study. One of the reasons why more patients on cefepime received glycopeptides in the present study could have been the open study design. It was noted that one-half of the modifications in the cefepime group were modified to ceftazidime during a primary or a new infection. Clinicians seemed to be more confident with a familiar drug (ceftazidime) and tempted to modify on the new drug (cefepime) regimen.
Another reason for the increased frequency of modification during our study was financial constraints under the national health insurance policy. In the United States and Europe monotherapy offers advantages of decreased toxicity and less cost compared with multidrug regimen. 4 However, monotherapy with cefepime or ceftazidime offers no economic advantage to the traditional combination therapy in our institution. The cost is 4 to 7 times that of the traditional combination therapy. Several febrile episodes responding to the study drugs were changed to traditional therapy after 3 days due to financial considerations.
The results of this study suggest that cefepime and ceftazidime are equally effective and safe for empiric treatment of febrile episodes in neutropenic patients. However, both drugs are more expensive than traditional combination antibiotic therapy. Background. Serogroup C meningococcal conjugate polysaccharide vaccines have been reported to induce significant serum IgG antibodies and immunologic memory in infants. Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local mucosal immune responses may play an important role in host defense against infection and carriage. We have investigated the mucosal IgA and IgG antibody responses to two meningococcal C conjugate vaccines in the saliva of healthy infants.
Methods. Specific salivary IgA and IgG antibodies to two meningococcal C polysaccharide conjugate vaccines (Menjugate from Chiron Corp., n ‫؍‬ 46; and Meningitec from Wyeth Lederle, n ‫؍‬ 54) were investigated by immunoassay in infants after parenteral vaccinations at the ages of 2, 3 and 4 months. Unstimulated saliva samples were collected immediately before the first immunization and 1 month after the third immunizations. Forty healthy infants receiving the same routine vaccines but no meningococcal C vaccine were recruited as controls.
Results. There were significant increases in meningococcal C polysaccharide-specific IgG antibody concentrations postvaccination compared with prevaccination concentrations in both vaccinated groups (both P < 0.001), but no change in the control group. There were no significant increases in specific IgA postvaccination geometric mean concentrations in either the vaccine or the control groups. The number of IgA positives postvaccination increased slightly in the Wyeth vaccine group vs. controls (P < 0.05).
Conclusions. Significant salivary IgG antibodies to meningococcal C polysaccharide were observed after parenteral immunization with two meningococcal C conjugate vaccines, whereas there was no significant increase in specific IgA antibody levels for these two vaccines.
INTRODUCTION
Meningococcus is the most common cause of bacterial meningitis and septicemia in children in the United Kingdom. The proportion of cases caused by serogroup C Neisseria meningitidis increased in the UK during the late 1990s. Children younger than 2 years have the highest attack rates.
1 Polysaccharide (PS) vaccines have been used against several encapsulated bacterial infections including Haemophilus influenzae, Streptococcus pneumoniae and N. meningitidis. Anti-capsular PS antibodies are bactericidal and are associated with protection. Meningococcal polysaccharide vaccines to several serogroups including C have been available for many years and are proved to be protective in adults. 2 However, like other PS antigens they are poorly immunogenic in young children. Hyporesponsiveness has also been reported after repeated doses of meningococcal C polysaccharide in children as well as in adults. [3] [4] [5] Serogroup C meningococcal conjugate polysaccharide vaccines have been developed and recently licensed in the UK. It has been reported that these vaccines induce significant serum IgG antibody responses and immunologic memory in infants. 6 -9 Because meningococcus is a mucosal pathogen colonizing the nasopharynx, local mucosal immune responses could play an important role in host defense against infection and carriage. We and others have reported mucosal IgG and IgA responses to such vaccines in adults and older children. 10, 11 Such responses could reduce nasopharyngeal carriage of meningococci and thus induce herd immunity, as has been seen with protein-conjugated polysaccharide vaccines against Haemophilus influenzae type b (Hib), widely used since the early 1990s. 12, 13 In this study we report mucosal IgA and IgG antibody responses to two meningococcal C conjugate vaccines in the saliva of healthy infants.
MATERIALS AND METHODS
Study subjects, vaccines and immunizations. Group 1 [vaccine: Chiron meningococcal C (MenC)
conjugate vaccine]. Forty-six healthy infants (24 male) age 7 to 10 weeks were studied who were recruited to a larger safety study (which involved 2500 healthy infants to assess the incidence of rare adverse events after Chiron MenC vaccine).
14 All subjects were immunized at 2, 3 and 4 months of age with Chiron MenC conjugate vaccine (Menjugate) injected intramuscularly into the anterolateral aspect of the right thigh. Each 0.5-ml dose of the vaccine contains 10 g of MenC PS conjugated to diphtheria toxoid (CRM197) protein carrier (12.5 to 33.3 g) and 1 mg of aluminum hydroxide (adjuvant) per dose. Subjects also received routine doses of diphtheria, tetanus and whole cell pertussisHib conjugate (Aventis Pasteur or Evans/SmithKline Beecham or Behring/Cynamid) and oral polio vaccine (SmithKline Beecham). At the same time 40 healthy infants (21 male) receiving the same routine vaccines but no MenC vaccine were recruited as controls.
Group 2 (vaccine: Wyeth Lederle MenC conjugate vaccine).
Fifty-four healthy infants (29 male) ages 7 to 10 weeks were studied who were recruited to a multicenter double blind Phase 2 immunogenicity trial. 15 All subjects were immunized at 2, 3 and 4 months with either a pilot lot or manufacturing lot (allocated randomly) of Wyeth Lederle meningococcal C conjugate vaccine (Meningitec) injected intramuscularly into the anterolateral aspect of the right thigh. The immunogenicity of the 2 lots was equivalent. 15 Each 0.5-ml dose of the vaccine contains 10 g of MenC oligosaccharide conjugated to diphtheria toxoid (CRM 197 ) protein carrier (15 g) and 0.5 mg of aluminum phosphate (adjuvant) per dose. Subjects also received routine doses of diphtheria, tetanus and whole cell pertussis-Hib conjugate vaccine [either Trivax (Evans/Wellcome) mixed with Hiberix (polyribosylribitol phosphate-tetanus toxoid; SmithKline Beecham) or ACTHIB diphtheria, tetanus and pertussis vaccine, Aventis Pasteur (AP polyribosylribitol phosphate-tetanus toxoid)] and oral polio vaccine.
Saliva samples. Unstimulated saliva samples were collected immediately before the first immunization and 1 month (4 to 6 weeks) after the third immunizations using a sponge swab, transported in dry ice and stored at Ϫ80°C until assay. The period of saliva storage was 3 to 6 calendar months.
Each study was approved by the South Sheffield local research ethics committee, and written informed consent was obtained from all parents before enrollment.
Immunoassay for salivary anti-MenC PSspecific IgG and IgA antibodies. Specific salivary antibodies against serogroup C meningococcal polysac-charides were determined with an enzyme-linked immunosorbent assay as described previously. 10 In brief Immulon 1 microtiter plates (Dynex, Chantilly, VA) were coated overnight at 4°C with meningococcal C PS (gift of Dr. George Carlone, CDC) 5 g/ml diluted in phosphate-buffered saline (PBS), containing methylated human serum albumin 5 g/ml (gift of Mike Bybel, Aventis Pasteur). After washes, 10% fetal bovine serum in PBS was added to block nonspecific binding. Diluted saliva samples (1/10 in PBS containing 10% fetal bovine serum) or standard serum (CDC 1992 reference, gift of Dr. George Carlone) were added to each well and incubated. Subsequently alkaline phosphatase-conjugated anti-human IgG (Sigma) was added for the IgG assay. Substrate (p-nitrophenyl phosphate) was added, and the plates were incubated further. Optical density (OD) at 405 nm was measured using a plate reader (Dynex), and concentrations of IgG were calculated by interpolation on the standard curve derived from serial dilutions of the reference serum (CDC 1992). For anti-meningococcal C PS-specific IgA measurements, the plates were incubated at room temperature (RT) on a horizontal rotator for 2 h after addition of samples. Murine monoclonal antibodies to human IgA (1/5000) was then added to the plates and incubated at RT for 2 h. Alkaline phosphataseconjugated goat anti-mouse antibodies (Stratech, Luton, UK) were added, and the plates were incubated overnight at RT. Subsequent procedures were as for the IgG assay. We do not use IgG background plate because the background OD is generally very low. For anti-meningococcal C PS-specific IgA, a plate coated with PBS only was used to control background for each assay; the OD values of samples and references on the PBS plate were subtracted from those coated with meningococcal C PS antigen. The mean [95% confidence interval (CI) in parentheses] background OD values on the PBS plate for IgA were 0.069 (0.054, 0.079) for salivary samples and 0.064 (0.052, 0.077) for reference serum.
For each assay a sample was considered positive if the mean of the 3 sample ODs was higher than the mean ϩ 2 SD of the 10 preimmunization samples which were pretested by immunoassay with no detectable antibodies (OD values not significantly different from PBS background).
Statistical analysis. Antibody concentrations were logarithmically transformed, and geometric mean concentrations (GMC) with 95% CI were calculated for each study group. Antibody titers below the limit of detection were arbitrarily assigned to one-half the lower limit of detection for each assay. The lower limits of detection for MenC IgG and IgA were 8 and 4 ng/ml respectively. Comparisons between pre-and postvaccination GMC within groups were made with paired two tailed Student t tests. The chi square test or Fisher's exact test where appropriate was used to compare the proportion of positive samples between pre-and postvaccination. Statistical analysis was done using SPSS for Windows (Version 9.0, SPSS Inc., Chicago, IL). P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Pre-and postvaccination meningococcal C PSspecific IgG and IgA salivary antibody concentrations and the number of antibody-positive samples are summarized in Table 1 . There were significant increases in specific IgG antibody concentrations postvaccination compared with prevaccination concentrations in both vaccinated groups (both P Ͻ 0.001), but no change in the control group. There were no significant increases in specific IgA postvaccination geometric mean concentrations in either the vaccine or the control groups. The number of IgA positives postvaccination increased slightly in the Wyeth vaccine group vs. controls (P Ͻ 0.05; Table 1 ).
The specific IgG and IgA antibody concentrations did not differ between those receiving the pilot and manufacturing lots of the Wyeth vaccine (data not shown).
DISCUSSION
The development of MenC conjugate vaccines has used the same technology as the highly successful protein-polysaccharide Hib conjugate vaccines. Conjugation of the polysaccharide to a protein carrier switches the immune responses to the polysaccharide antigen from T cell-independent to T cell-dependent, 16 which results in an effective primary immune response in all age groups, including infants. Hib infection is now rarely seen in the UK and its disappearance after the introduction of universal primary immunization in 1992 was more rapid than expected. This appears to have been a result of the induction of significant mucosal immunity and thus herd immunity through reduction in upper respiratory carriage rates. 17, 18 There is evidence that this mucosal immunity may have resulted from induction of significant antibody responses and that salivary IgG may be important as well as IgA. 18 It has been suggested that antibody responses to immunization with polysaccharide vaccines depend on a number of factors including age, vaccine dose and dose regimen and the degree of preexisting natural immunity. 19, 20 Different polysaccharide vaccines including meningococcal A and C and pneumococcal polysaccharide have resulted in dramatic reductions in disease incidence and, it is suggested, in herd immunity. 21, 22 Reduction in nasopharyngeal carriage after polysaccharide vaccination has also been reported. 2, [23] [24] [25] Mucosal IgA and IgG could be important in these effects, but the mechanisms by which these mucosal antibodies reduce carriage are unclear. Both secretory IgA-and IgG-specific antibodies have been shown to inhibit Hib colonization. 26 Although the capsule is not known as an adhesin, anti-capsular polysaccharide antibodies may inhibit the adherence by coating the surface of the bacteria and sterically hindering the adherence to the epithelium. 27 Complement-and specific antibody-mediated phagocytosis could also be involved in the clearance of encapsulated bacteria from the mucosal surface.
In this infant study both Chiron and Wyeth MenC conjugate vaccines induced significant production of salivary MenC PS-specific IgG antibodies. For IgAspecific antibodies, although there was a relative increase in the percentage of positives in one vaccine group compared with the control group, the geometric mean concentrations of IgA were not significantly increased after three doses of either vaccine. Because these MenC conjugate vaccines induce strong serum IgG responses, the former finding is expected, because salivary IgG is likely to be derived from the serum pool. However, the latter is in contrast to our previous report 10 of mucosal responses to a single dose of the same Chiron MenC conjugate vaccine in adolescents and also in contrast to a previous report in infants by Borrow et al., 28 which showed significant salivary IgA production to a different vaccine. Salivary IgA is likely to be locally produced in secretory form. 10, 17, 28 The demonstrated lack of significant local specific IgA production in infants (compared with adolescents) to the same Chiron MenC conjugate vaccine may be the result of a relative inefficiency of IgA induction mechanisms including T and B cell or antigen-presenting cell function in infants after parenteral immunization. The varying immunogenicities of different vaccine preparations might account for the apparent disagreement in the IgA results between this study and that by Borrow et al. 28 in which a bivalent meningococcal A and MenC PS conjugate vaccine was used. The quantities of MenC PS and protein carriers were different (10 g and 12.5 to 33.3 g, respectively, in this study vs. 11.7 g and 48.7 g). Our preliminary results from another study involving a different MenC PS conjugate vaccine show salivary IgA as well as IgG production in infants after primary immunization (unpublished data). These results suggest that the induction of mucosal IgA immune responses in infants varies among different vaccine preparations. The relative inefficiency of significant production of salivary IgA after primary immunizations does not completely exclude the possibility of mucosal memory responses after reexposure to the antigen as we have previously shown for other polysaccharide antigens, 29 although it should be noted that Nurkka et al. 30 did not show evidence of mucosal memory in previously vaccinated Gambian children to 
